Jazz Pharmaceuticals (JAZZ) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenues ranged from $897.8M to $902M, with strong growth in Xywav (up 9% YoY) and Epidiolex (up 10% YoY), offset by declines in oncology and Xyrem, and temporary headwinds in oncology.

• Completed Chimerix acquisition (costing $935M), adding dordaviprone to the pipeline and incurring significant IPR&D expense.

• Affirmed 2025 revenue guidance of $4.15–$4.4 billion, representing 5% YoY growth at midpoint, with continued investment in pipeline and commercial execution.

• Submitted sNDA for Zepzelca first-line maintenance in SCLC and received positive CHMP opinion for zanidatamab in advanced HER2-positive BTC in the EU.

• Net loss for Q1 2025 was $92.5M, primarily due to $172M in Xyrem antitrust litigation settlements.

Financial highlights

• Xywav net sales: $344.8M–$345M (+9% YoY); Epidiolex net sales: $217.7M–$218M (+10% YoY).

• Oncology revenues declined 11% YoY to $229M, with Rylaze down 8% and Zepzelca down 16%.

• Adjusted net income for Q1 2025 was $105M ($1.68/share), down from $178M ($2.63) in Q1 2024, reflecting $146M after-tax impact from Xyrem litigation.

• Operating cash flow for Q1 2025 was $429.8M–$430M; cash and investments totaled $2.6B at quarter end.

• SG&A expenses rose to $514M (up 46%), driven by litigation settlements; R&D expenses decreased to $180.7M (down 19%).

Outlook and guidance

• 2025 revenue guidance affirmed at $4.15–$4.4B (5% YoY growth at midpoint).

• Non-GAAP net income guidance for 2025: $250–$350M; GAAP net loss guidance: $(615)–$(450)M.

• SG&A expected to rise in 2025 due to litigation and Chimerix integration; R&D to decrease with focus on prioritized assets.

• Epidiolex expected to reach blockbuster status in 2025; Xywav remains #1 in narcolepsy and only approved IH therapy.

• Confident in ability to generate positive operating cash flow and de-lever balance sheet.